A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

British Journal of Dermatology

Volumn 174, Issue 6, 2016, Pages 1266-1276

  Papp, K A ^a   Menter, M A ^b   Raman, M ^c   Disch, D ^d   Schlichting, D E ^d   Gaich, C ^d   Macias, W ^d   Zhang, X ^d   Janes, J M ^d  

^a K Papp Clinical Research and Probity Medical Research   (Canada)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Centre for Dermatology and Probity Medical Research   (Canada)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BARICITINIB; CREATINE KINASE; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO;

ABNORMAL LABORATORY RESULT; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INFESTATION; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; NORTH AMERICAN; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84975106324     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14403     Document Type: Article

References (29)

1. Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005; 141:1537–41.
2. Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–85.
3. Braun-Falco O, Burg G. [Inflammatory infiltrate in psoriasis vulgaris. A cytochemical study]. Arch Klin Exp Dermatol 1970; 236:297–314 [German].
4. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301:555.
5. Bos JD, Hulsebosch HJ, Krieg SR et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275:181–9.
6. Menssen A, Trommler P, Vollmer S et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995; 155:4078–83.
7. Cerio R, Griffiths CEM, Copper KD et al. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 1989; 121:421–31.
8. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496–509.
9. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127:871–84.
10. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32:227–55.
11. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
12. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014–22.
13. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106–15.
14. Papp KA, Kaufmann R, Thaçi D et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013; 27:e376–83.
15. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84.
16. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367–74.
17. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178:2623–9.
18. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3:900–11.
19. Bachelez H, van de Kerkhof P, Strohal R et al. Comparison of tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomized trial. Paper presented at the 72nd Annual Meeting of the American Academy of Dermatology, 21–25 March 2014; Denver, CO.
20. Boy MG, Wang C, Wilkinson BE et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009; 129:2299–302.
21. Papp KA, Menter A, Strober B et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:668–77.
22. Shi JG, Chen X, Lee F et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014; 54:1354–61.
23. Keystone E, Taylor P, Drescher E et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015; 74:333–40.
24. Keystone EC, Taylor PC, Genovese MC et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. Arth Rheum 2014; 66:S1232.
25. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamics effects. Clin Pharmacol Ther 1994; 56:406–19.
26. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304–12.
27. Lamel SA, Myer KA, Younes N et al. Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment. Arch Dermatol Res 2012; 304:707–17.
28. Pesu M, Laurence A, Kishore N et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223:132–42.
29. Strober B, Buonanno M, Clark JD et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013; 169:992–9.